In the age of information and patient-centered care, new methods of delivering postoperative care must be developed and evaluated.
I n the age of patient-centric care, delivery models must evolve to become more convenient for patients and costeffective to the health system, while also maintaining a high degree of patient satisfaction and convenience. Many centers are now substituting in-person follow-up care with care delivered via telephone or a mobile app. [1] [2] [3] [4] [5] [6] Studies show that these remote modes of follow-up are safe and that patients are as equally satisfied with them as they are with in-person follow-up care. [1] [2] [3] [4] [5] [6] Women's College Hospital in Toronto, Ontario, Canada, offers specialized surgical procedures, including breast reconstruction typically following mastectomy for breast cancer. The goal of surgery is to restore a breast mound and improve the quality of life of cancer survivors. [7] [8] [9] These procedures are performed on an ambulatory basis; all patients go home on the day of or the day after surgery. Patients often travel significant distances to receive this care. Traveling for surgery is not unique to patients who undergo breast reconstruction; surgical care programs have become regionalized to ensure higher volumes in specific centers of excellence, which means that more patients travel to receive that care. 10, 11 In general, the morbidity and mortality rates following ambulatory surgery are very low. 12 Complication rates in this subset of patients undergoing breast reconstruction are approximately 5% to 7.5%, 13,14 making most follow-up visits perfunctory.
The QoC Health Inc mobile app allows patients to submit photographs and answers to a validated quality of recovery questionnaire and a pain visual analog scale using a mobile device for the first 30 days after the operation. Surgeons are able to follow patient reports on a web portal. This technology has been used for patients who have undergone ambulatory breast reconstruction. 15 Our study builds on preexisting data 15,16 by determining whether receiving follow-up via the mobile app can avert the need for in-person follow-up care.
Methods
This pragmatic, single-center, open, controlled, 2-arm parallelgroup superiority randomized clinical trial was conducted from February 1 to August 31, 2015, to compare follow-up care delivered via mobile app vs in person during the first 30 days following ambulatory breast reconstruction. Permutated-block randomization was conducted by blocks of 4 to 6 using the program RALLOC in Stata statistical software (StataCorp). 17 The complete research protocol is available in the Supplement. 18 This study complies with the standards outlined in the TriCouncil Policy Statement and was approved by the Women's College Hospital Research Ethics Board. During a 5-month period, eligible patients were consecutively approached by a senior author not directly involved in patient care (K.A.A.) during their preoperative visits, and written informed consent was obtained. All ambulatory patients undergoing elective breast reconstruction at Women's College Hospital were included in this study. Patients had to be able to use a mobile device and communicate in English. All patients were nonsmokers with a body mass index of 30 or less (calculated as weight in kilograms divided by height in meters squared) because these are requirements for ambulatory breast reconstruction. Patients were excluded if they experienced chronic pain, were taking narcotic (morphine-like) medication for pain on a regular basis, or had an allergy to local anesthetics or morphine-like medications. Pain ratings captured in the pain visual analog scale and quality of recovery 9-item questionnaire are important for judging the quality of postoperative recovery. Preexisting pain or an inability to take narcotics would compromise the reliability of these measures.
Procedures were performed by 3 surgeons (M.B., B.B., and J.L.S.), with more than 90% of cases being performed by 2 surgeons within this group of surgeons. Randomization was performed by an outside statistician and occurred in equal proportions (1:1) between those using the mobile app and those receiving in-person follow-up care. After a patient agreed to participate in the study, she was provided a sequentially numbered envelope containing her group assignment by the enrolling senior author. All patients received what is currently the standard of care in this hospital. Patients in the conventional follow-up group had planned clinic follow-up at approximately 1 week and 4 weeks after the operation. This is the follow-up schedule currently used by all surgeons.
The mobile app follow-up group had no planned inperson follow-up at 1 week and 4 weeks after the operation. However, these visits were replaced with an examination of the surgical site via photographs submitted through the mobile app, as well as monitoring of the results of the pain visual analog scale, and quality of recovery 9-item questionnaire. Patient reporting began after discharge from the recovery room. Since 75% of complications occur within the first 2 weeks of discharge, 12 we used daily monitoring for 2 weeks and then weekly monitoring for the remaining 2 weeks (totaling 30 days of monitoring). Patients were reminded by email to complete regular reporting if a submission was not received. The data entered through the mobile app reached a double-encrypted server. The surgeon used a wireless interface to access those data and monitor the patient's condition (not in real time). High pain scores were flagged in the database for quick viewing. Any red flags (abnormally high pain scores or abnormally low quality of recovery 9-item questionnaire scores) prompted in-person follow-up. Physicians summarized the clinical findings recorded by the mobile app using the prototypical subjective, objective, assessment, and plan note 19 at 1 or more time points during the 30-day monitoring period.
Outcome Measures
The main outcome was the total number of follow-up visits (including specialists, family physician, and emergency department) associated with the surgery. These data were captured at 30 days after the surgery by patient survey and reconfirmed via review of the medical record. The secondary outcomes included the total number of telephone calls and emails to the health care team associated with the surgery, satisfaction and convenience scores, and postoperative complications. All secondary outcome data were captured by telephone survey 30 days after the surgery. Patientreported satisfaction and convenience scores were recorded using a 5-point Likert scale. Complications were defined as adverse events that were attributed to the surgery and required a medical or surgical intervention.
Statistical Analysis
Descriptive statistics (frequencies and mean [SD] values) were calculated for all clinical and outcome variables. All data obtained in this study were entered into Excel and analyzed using Stata version 13 (StataCorp LP).
We used person-level Poisson regression to determine if there was a statistically significant difference between patients using the mobile app and those receiving in-person follow-up care in count data including the number of in-person follow-up visits attended, the number of telephone calls and emails to health care professionals, and the 5-point patient-reported satisfaction and convenience scores. The goodness of fit of all Poisson regression models was confirmed with the χ 2 test. Complications were recorded as a binary variable. A 2-sample test of proportions was used to determine if there was a statistically significant difference in complication rates between patients using the mobile app and those receiving in-person follow-up care. A covariate adjustment was performed if any of the relevant variables remained unbalanced after randomization. The average patient who underwent breast reconstruction attends 2 in-person follow-up visits within the first month after surgery. We assumed that we could avert at least 1 in-person visit in the group using the mobile app and that we would have an equal number of participants in both groups. Therefore, the E test between 2 Poisson mean values for count data was used to generate a sample size of 64 (32 patients per group) at a power of 95% (α = .05). 20 Assuming a 10% dropout rate, we increased the sample size target to 36 patients per group. The study was also powered to detect a 5-percentagepoint difference in the complication rates between groups using the Fisher exact test comparing 2 independent proportions (α = .05). This magnitude of increase was thought to be a clinically relevant difference given the known variability in the rates of complication reported in the literature.
21

Results
Demographic and Surgical Data
A total of 77 eligible patients were approached consecutively during the 5-month study period. Figure 1 demonstrates the flow scheme of all study patients. A total of 65 patients were enrolled in the study: 33 completed in-person follow-up care and 32 completed mobile app follow-up care. No patients were lost to follow-up. There were no missing data. The trial was completed 30 days after the final patient had surgery. See the Table for patient demographics. Major surgery was defined as a bilateral mastectomy and immediate reconstruction or a delayed pedicled autologous breast reconstruction based largely on the length and complexity of the procedures. Using a lenient P value of .10, we found that prior radiotherapy (8 [24%] vs 15 [47%]) and mean distance from the hospital to the patient's home (120 vs 53 km) were unbalanced between the inperson and mobile app groups. All other variables were well balanced (Table) .
Total Number of In-Person Follow-up Visits During the First 30 Days
The in-person group attended a mean 1.64 in-person visits during the first 30 days after surgery (median, 2 visits; range, 0-4 visits). This mean includes 3 patients who visited the emergency department. The mobile app group attended a mean 0.66 in-person visits during the first 30 days after surgery (median, 1 visit; range, 0-3 visits). No patients in the mobile app group visited the emergency department. The mobile app group was 0.40 times less likely to attend in-person follow-up care during the first 30 days after surgery compared with the in-person group (95% CI, 0.24-0.66; P < .001). This difference was maintained at 3 months postoperatively (incidence rate ratio [IRR], 0.66; 95% CI, 0.46-0.95; P = .03).
The number of patients who underwent prior radiotherapy and the distance from the patient's home to the hospital remained unbalanced between the 2 groups after randomization. It is reasonable to anticipate that patients who underwent prior radiotherapy may require more follow-up because of a higher potential of delayed wound healing and other complications. It is also reasonable to anticipate that patients who live further from the hospital may attend fewer inperson follow-up visits. After adjustment for these covariates, the significant difference in the number of in-person follow-ups during the first 30 days after surgery was robust between the in-person group and the mobile app group (prior radiotherapy: IRR, 0.42; 95% CI, 0.25-0.70; P = .001; and distance from home to the hospital: IRR, 0.38; 95% CI, 0.23-0.64; P < .001).
Total Number of Emails and Telephone Calls During the First 30 Days
The group receiving in-person follow-up care made a mean 0.30 telephone calls to their health care professionals during the first 30 days after surgery (median, 0 telephone calls; range, 0-2 telephone calls). The group using the mobile app made a mean of 0.31 telephone calls during the first 30 days after surgery (median, 0 telephone calls; range, 0-2 telephone calls). There was no statistically significant difference between groups (IRR, 1.03; 95% CI, 0.43-2.48; P = .95). However, the group using the mobile app did send more emails than did the inperson group during the first 30 days after surgery (IRR, 4.13; 95% CI, 1.55-10.99; P = .005). The group using the mobile app sent a mean of 0.65 emails (median, 0.5 emails; range, 0-3 emails) and the in-person group sent a mean of 0.15 emails (median, 0 emails; range, 0-1 emails). These findings were robust after adjustment for the unbalanced covariates of prior radiotherapy and distance from the patient's home to the hospital (IRR, 4.38; 95% CI, 1.62-11.84; P = .004 and IRR, 4.84; 95% CI, 1.69-13.84; P = .003, respectively).
Patient-Reported Satisfaction and Convenience Scores
Satisfaction and convenience scores were garnered using a 5-point Likert scale ( Figure 2 and Figure 3 ). There was no statistically significant difference in satisfaction scores between groups (IRR, 0.95; 95% CI, 0.76-1.20; P = .70). However, the group using the mobile app reported higher convenience scores than did the group receiving in-person follow-up care (IRR, 1.39; 95% CI, 1.09-1.77; P = .008). Thirty-one patients in the mobile app group (97%) agreed or strongly agreed that the type of follow-up care they received was convenient. Only 16 patients in the in-person group (48%) agreed or strongly agreed that the type of follow-up care they received was convenient. Again, because the covariates of prior radiotherapy and the distance from the patient's home to the hospital remained unbalanced between groups after randomization, we adjusted for these covariates and found that the significant difference in the convenience scores between the mobile app group and the in-person group was robust (IRR, 1.39; 95% CI, 1.08-1.79; P =.01 and IRR, 1.35; 95% CI, 1.05-1.73; P = .02, respectively).
Complications
Four patients in the in-person group developed a postoperative complication. Two patients developed superficial infections at the incisional surgical site 22 requiring oral antibiotics, 1 patient A growing number of procedures, including complex operations such as autologous breast reconstruction, are offered in an ambulatory setting. Patients using the mobile app require approximately 2 minutes to input the quality of recovery, pain visual analog scale, and photographs of the surgical site. This ease of use allows patients to submit data frequently (ie, daily or weekly), providing a continuous, richer inflow of information than could ever be achieved by telephone or in-person follow-up care. As we look for ways to improve clinical care, the granular data collected via the mobile app could be used to augment the National Surgical Quality Improvement Programs occurring across the country.
27,28
Limitations
The limitations of this trial include the single ambulatory patient population. These findings are likely generalizable to other ambulatory patient populations, given the similar findings already discussed, but are not generalizable to individuals receiving inpatient breast reconstruction. In addition, we were unable to conduct the study in a blinded fashion owing to the nature of the intervention. We did not power our study to detect a significant difference in the number of emergency department visits between groups. This is an unexpected and important finding that should be investigated in the future.
Conclusions
Mobile app follow-up care is suitably targeted to low-risk postoperative ambulatory patients. Patients using the mobile app attended 0.40 times fewer in-person visits for follow-up care and sent more emails to their health care professionals during the first 30 days after surgery than did patients in the in-person follow-up group. The mobile app group was more likely than the in-person group to agree or strongly agree that their type of follow-up care was convenient. Complication rates and patient satisfaction scores were comparable between the groups. These are important findings given the current demands on the health care system and the push toward patient-centric care. In the future, we will report on the cost-effective nature of this solution. 
LOCATION(S) WHERE THE RESEARCH WILL BE CONDUCTED:
31 32
If the research is to be conducted at a site requiring administrative approval/consent (e.g., in a school), please include all 105 106
x The review was/will be specific to this protocol 107 108
The review was/will be part of a larger grant Dr. John Semple is a shareholder in QoC Health Inc, the company that owns the rights to smartphone app used in this study. Describe the purpose and scholarly rationale for the proposed project. State the hypotheses/research questions to be examined.
148
The rationale for doing the study must be clear. Please include references in this section.
150
Increasingly, telemedicine is used to overcome distance patients must travel to receive specialized care. Previous studies have 151 safely utilized telemedicine follow-up care in ambulatory surgical patients to improve access to care. These studies 152 demonstrate that it is possible to safely improve access to necessary services with cost-and time-savings to patients and 153 providers using telemedicine.
155
METHODS
157
(a) Please describe all formal and informal procedures to be used. Describe the data to be collected, where and how they will 158 be obtained and how they will be analyzed.
159 160
This will be a pragmatic, single-centre, open, controlled, 2-arm parallel-group superiority randomized trial comparing mobile 161 app and in-person follow-up care over the first 30 days following surgery. Permutated-block randomization will be conducted 162 by blocks of 4-6 using the program ralloc in Stata statistical software.
164
The primary outcome is the total number physician visits related to the surgery over the first month postoperative. The 
205
Sequence Generation: A block randomization scheme with variable block size will be generated using STATA ralloc.ado 14.
206
This will ensure approximately equal sample size, and that participants and study staff cannot anticipate assignment to either 207 group. Treatments will be allocated in a 1:1 ratio. All the study investigators and staff will be blinded to the block number, 208 block size and sequence in the block. The treatments will be assigned via pre-prepared sealed, opaque envelopes and the 209 envelopes will be ordered in the sequence of treatment assignments generated by the STATA code. Once eligibility for 210 randomization has been determined, the first available allocation envelope will be assigned to the study subject. The subject 211 will be randomized to the treatment arm indicated inside the envelope.
212
Allocation concealment: As potential subjects are identified, a research assistant will be notified to assess eligibility. Once a 213 subject is deemed eligible for enrolment, has given the necessary informed consent, has been enrolled, and has had her will be given to the study coordinator. The study biostatistician will retain the key to treatment assignments. The PI (KA) and 224 study coordinator will enroll patients. The study coordinator will assign participants to an intervention and be on site to ensure 225 compliance with the study protocol.
227
Blinding: Due to the nature of the intervention, participants and surgeons cannot be blinded to the study. The PI (KA) will be 228 involved in patient recruitment and analysis; therefore, it will be impossible to blind her to the patient arms. An independent 229 review board will review the findings of this study prior to publication, and they will be blinded to the treatment arm.
231
Statistical Methods
232
Descriptive statistics (frequencies, means, standard deviations) will be calculated for all clinical and outcome variables.
233
Baseline demographics will be compared using a chi-square test for categorical variables and a t-test or Wilcoxon Rank Sum 234 test for continuous variables. All data obtained in this study will be entered into Excel and analyzed using STATA 13. A two-235 sided p-value of ≤ 0.05 will be considered statistically significant. 
244
Baseline differences in complications will be compared using a chi-square test for categorical variables (complication = event; 245 no complication = no event). Baseline differences in societal and health care system costs will be compared using Wilcoxon
246
Rank Sum test for non-normally distributed, continuous data.
248
We will perform a person-level net benefit regression to determine the cost-effectiveness of this intervention. We will define 249 cost as all "societal costs incurred over the 30-days after surgery". We will define effect as the "complication rate over the 30-250 days after surgery". We will regress net benefit (dependant variable) on study arm, age, distance from home to hospital (km),
251
BMI, BMI2, ASA classification, smoking status, radiation status, and major or minor procedure (independent variables). We 252 will perform regression diagnostics. We will use these diagnostics to advise on the use of parametric vs. non-parametric 253 generation of 95% confidence intervals. We will use our net benefit regression to generate an incremental net benefit (INB). In 254 this situation, where willingness to pay is unknown, we assigned numerous values for willingness to pay and generated a cost-255 effectiveness acceptability curve (CEAC) based on these theoretical values 20. The CEAC illustrates the probability that the 256 intervention is cost-effective by graphing the probability that B1 > 0 as a function of WTP21.
258
Finally, we will run a person-level poisson regression to determine if there is a difference in patient satisfaction scores between 259 the two groups.
261
Handling Missing Data: We will compare baseline characteristics between patients with and without missing data. We will 262 generate "best" and "worst" case scenarios for the missing data to determine if there is any change in findings. We will consult 
277
All patients will complete this at week two and week four. Women's College Hospital will be approached for inclusion in this study.
295
Exclusion criteria: Exclusion criteria: Pain ratings captured in the VAS and QoR9 are important for judging quality of 296 postoperative recovery. Pre-existing pain or an inability to take narcotics would compromise the reliability of these measures.
297
Therefore, patients must not suffer from chronic pain. They must not be taking narcotic (morphine-like) medication for pain on Accommodation of special populations: Patients with hearing or speaking impairments will be accommodated with the help of 301 translator. The person who regularly attends visits with her will facilitate this, or if no such person is available, we will use a 302 hospital translator. All patients will receive an explanation of the study and the consent form in writing. All material will be 303 understandable by patients with a grade 6 reading level. If our patients have lower than a grade 6 reading level, we will ask 304 them if there is a family member at home who could assist them with the use of the mobile device.
306 307
Once REB is approved we will approach consecutive breast reconstruction patients, who meet the inclusion criteria. A member 308 of the healthcare team will inform patients about the study prior to surgery. At that time, they will be introduced to the 
EXPERIENCE OF INVESTIGATORS WITH THIS TYPE OF RESEARCH
338 339 (a) Please provide a brief description of previous experience with this type of research by (i) the principal 340 investigator/supervisor or sponsor, (ii) the research team and (iii) the people who will have direct contact with the participants.
341
If there has not been previous experience, please describe how the principal investigator/research team will be prepared. 
RECRUITMENT OF PARTICIPANTS
357
• Where there is recruitment, please describe how, by whom, and from where the participants will be recruited
• Where participant observation is to be used, please explain the form of insertion of the researcher into the research setting 359 (e.g., living in a community, visiting on a bi-weekly basis, attending organized functions)
360
• If relevant, describe any translation of recruitment materials, how this will occur and whether or not those people 361 responsible for recruitment will speak the language of the participants. 
438
Once REB is approved we will approach consecutive breast reconstruction patients, who meet the inclusion criteria. The review and sign the appropriate consent form. They will have the opportunity to discuss the study with the attending surgeon.
445
Written consent will be obtained for all prospective patients. After the patient has consented to the trial, they will be 446 randomized to the mobile app or in-person follow-up arm using the program ralloc in Stata statistical software.
448
The mobile app follow-up group will submit a "test run" with the assistance of the nurse when they are recovering from the project is complete (e.g., report, poster presentation, pamphlet, etc.) and note how participants will be able to access this 503 information.
505
A report will be mailed to all participants. A website will be designed at WCH that will also relay the study results.
507
PARTICIPANT WITHDRAWAL
509
(a) Where applicable, please describe how participants will be informed of their right to withdraw from the project and outline 510 the procedures that will be followed to allow them to exercise this right.
512
The participants will be informed of their right to withdraw at: 1) time of consent, 2) a smartphone "test run" will be submitted 
518
We will clarify if patients wish to withdrawal from the smartphone follow-up arm or the entire study. If the patient wishes to 519 withdrawal from the smartphone follow-up arm, we will clarify that we can include their data based on the intention to treat. (IaaS) and cloud computing services (SaaS) for seamless accessibility, redundancy, and scalability were also utilized.
546
All data will be de-indentified using patient identification numbers. The key will be stored on site, under lock and key, in the The deadline for delegated review (SSH&E or HS) is EVERY Monday, or first business day of the week, by 4 pm.
SECTION F -LEVEL OF RISK AND REVIEW TYPE
584 See the Instructions for Ethics Review Protocol Submission Form for detailed information about the Risk Matrix.
617
Information about full REB meeting and submission due dates are posted on our website (SSH&E, HS or HIV).
619
HIV REB reviews all protocols at full board level but applies proportionate review based on the level of risk.
621
All other submissions (e.g., amendments, adverse events, and continuing review submissions) should be sent to We are asking you to participate in this study so that we can see if we can use mobile app follow-up to avert in-person visits.
708
We will measure the "net benefit" for society in terms of cost savings per visit. We will evaluate whether mobile app follow-709 up will save our patients and the hospital money. We will evaluate for a difference in the number of problems related to 710 surgery between patients that participate in mobile app versus in-person follow-up care. We think that there will be no After you have enough time to learn and think about the study, we will ask you for your consent to participate. This may occur 726 up to two months prior to surgery. At this point, you will be randomly (i.e. by chance, like a flip of a coin) assigned to one of 727 two groups:
729
In Group A, you would receive standard follow-up after surgery. There will be no requirements before surgery. You would 730 come in for your regular appointment at one-and 4-weeks after surgery. At each of these appointments, we would ask you to 731 fill out a small quality of recovery-9 (QoR-9) questionnaire and pain visual analog scale (VAS). We would have our study 732 coordinator call you at home at 2-and 4-weeks after surgery. The study coordinator would ask you about any expected or 733 unexpected interactions (e.g. visits or telephone calls) with a health care worker related to your surgery, any problems that 734 you've experienced related to your surgery, any costs that you've incurred related to your surgery, and your satisfaction with 735 your care.
737
In Group B, you would receive mobile app follow-up after surgery. We would give you a smartphone for the duration of the 738 30-day study. You would use the device free of charge but must return it in good condition as they are on loan. We would 739 supply a paid-postage envelope that you can use to return the phone at the end of the study. You would be asked to meet with 740 the study coordinator on the day you come to see your surgeon or to the Preadmission Unit. At this time, she/he will explain 741 how to use the mobile app and review the 2 questionnaires that you will be asked to complete after the surgery to assess the If you agree to participate in this study, you may or may not benefit from the study. The information we gather from this study 798 will help us gain insight into the after surgery patient experience at home and make modifications to enhance the quality of 799 recovery and patient satisfaction following surgery in the future. 800 801 In no way does signing this consent form waive your legal rights nor does it relieve the investigators, sponsors or involved 811 institutions from their legal and professional responsibilities.
RIGHTS AS A VOLUNTEER
812
There is no payment for your participation in this study, and you will not have to pay for anything extra by participating in this 813 study.
815
CONFIDENTIALITY
817
We will respect your privacy. Any of your personal health information (information about you and your health that identifies 818 you as an individual) collected or obtained, whether you choose to participate or not, will be kept confidential and protected to 819 the fullest extent of the law. All personal health information collected will be kept in a secure location. The study staff and the 820 WCH Research Ethics Board may look at your personal health information for purposes associated with the study, but will 821 only be allowed to see your records under the supervision of the Principal Investigator and will be obligated to protect your 822 privacy and not disclose your personal health information. Your personal information will not be given to anyone without your 823 permission, unless this is permitted or required by law.
825
Only members of the research team will have access to your personal health information. Once the initial data is collected for 826 the study, only a personal identification number assigned at the beginning of the study will identify you as a participant, no 827 names or other identifiers will be used. However, in order to support your care at Women's College Hospital, the personal 828 identification number will be lifted in order to place an account of your virtual visit in your health record held securely at the 829 hospital. The anonymized questionnaires you complete and other study information will be held securely by QoC, a sponsor of 830 the study. QoC owns the technology used to transmit the questionnaires, and also securely stores the study data on behalf of 831 Women's College Hospital for a period of 5 years as approved by the WCH Research Ethics Board. QoC's employees and 832 agents sign confidentiality agreements and QoC is bound by contract to protect your information.
834
The following information will be collected from your chart and study questionnaires: This information is collected so that we can answer the study questions including: Certain factors like radiation status impact the chance of complication, and therefore this information is collected too. The 854 information we report will be anonymous and consist of responses from groups of people, not individuals. This includes all scientific/academic presentations and publications. No surgical site photos submitted by smartphone will be published in an 856 educational presentation or medical journal unless secondary photo consent is obtained from a particular patient after the fact.
858
All questionnaires will be stored in a locked filing cabinet. Electronic files will be stored on a password-protected computer on 859 the secure QoC server located in Canada and will otherwise be accessible only to members of the research team doing the data 860 analysis.
862
You maintain the right to withdraw your personal health information, medical health records, survey responses from use in the 863 study at any time. However, this would not be feasible after publication of the study, but all future write-ups would not include 864 your data, as so requested.
866
STUDY WITHDRAWAL AND DISCLOSURE OF NEW INFORMATION
868
Patients may choose to leave this study at any time by contacting the office of Dr. Semple at (416) 323-7555. A decision to 869 leave the study will in no way impact the care you receive.
871
New information that may impact a subject's willingness to continue with or withdraw from the study will be provided to the 872 subject or the subject's legally acceptable representative in a timely manner. You will be given a copy of this informed consent form after it has been signed and dated by you and the study staff. 
